Post-market Clinical Follow-up of a Magnetic Bone Conduction Implant (Cochlear Baha Attract System)
Summary
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Hearing Performance: Threshold Audiometry PTA4: Unaided Versus Baha Attract |
-21.0; -20.9; -21.5 | <0.0001 sig |
| PRIMARY Hearing Performance: Change in Threshold Audiometry: Unaided Versus Baha Attract |
-16.9; -26.6; -26.4; -18.7; -16.9; -12.3 | <0.0001 sig |
| PRIMARY Hearing Performance: Change in Threshold Audiometry: Unaided Versus Baha Attract |
-16.9; -26.6; -26.4; -18.7; -16.9; -12.3 | <0.0001 sig |
| PRIMARY Hearing Performance: Change in Threshold Audiometry: Unaided Versus Baha Attract |
-16.9; -26.6; -26.4; -18.7; -16.9; -12.3 | <0.0001 sig |
| SECONDARY Adaptive Speech Recognition in Noise Ratio: Unaided Versus Baha Attract |
-4.30; 4.79; -4.47 | <0.0001 sig |
| SECONDARY Speech in Quiet, Baha Attract Versus Unaided |
52.1; 43.4; 13.3; 50.7; 45.5; 13.9 | <0.0001 sig |
| SECONDARY Hearing Performance: Threshold Audiometry PTA4: Sound Processor on Softband Versus Baha Attract |
-0.62; 0.196; -0.136 | 0.38 |
| SECONDARY Hearing Performance: Threshold Audiometry Individual Frequencies: Baha Attract Versus Sound Processor on Softband |
-3.67; -1.74; -1.20; -0.761; 2.61; 3.15 | 0.0051 sig |
| SECONDARY Hearing Performance: Threshold Audiometry Individual Frequencies: Baha Attract Versus Sound Processor on Softband |
-3.67; -1.74; -1.20; -0.761; 2.61; 3.15 | 0.0051 sig |
| SECONDARY Hearing Performance: Threshold Audiometry Individual Frequencies: Baha Attract Versus Sound Processor on Softband |
-3.67; -1.74; -1.20; -0.761; 2.61; 3.15 | 0.0051 sig |
| SECONDARY Adaptive Speech Recognition in Noise Ratio: Baha Attract Versus Sound Processor on Softband |
-0.508; -1.05; -0.739 | 0.46 |
| SECONDARY Speech in Quiet: Baha Attract Versus Sound Processor on Softband |
2.74; -2.11; -0.33; 0.373; -2.69; -0.961 | 0.43 |
| SECONDARY Health Utility Index (HUI) |
0.063; -0.003; 0.111; 0.045; -0.016; -0.021 | 0.088 |
| SECONDARY Abbreviated Profile of Hearing Aid Benefit (APHAB) |
20.4; 26.3; 22.0; 1.32; 22.9; 18.7 | <0.0001 sig |
| SECONDARY Speech, Spatial and Qualities of Hearing Scale (SSQ) |
2.49; 1.87; 1.68; 2.07; 1.36; 1.30 | <0.0001 sig |
| SECONDARY Time to Perform Surgery |
38.7 | — |
| SECONDARY Tissue Reduction Performed During Surgery |
12; 42 | — |
| SECONDARY Implant Stability |
77.3 | — |
| SECONDARY Magnetic Force |
1.01; 1.07; 1.15; 1.16; 1.15; 1.09 | — |
| SECONDARY Sound Processor Magnet Choice |
19; 19; 9; 6; 1; 0 | — |
| SECONDARY Pain & Discomfort |
21; 15; 15; 2; 24; 16 | — |
| SECONDARY Numbness When Tested With a Pin |
12; 9; 33; 15; 7; 32 | — |
| SECONDARY Numbness When Tested With a Cotton Swab |
13; 9; 32; 18; 6; 30 | — |
Eligibility Criteria
Inclusion Criteria
Adult subject, i.e. ≥ 18 years of age
Conductive or mixed hearing loss in the ear to be implanted:
Bone conduction thresholds with a pure tone average PTA4 of < 30 dB hearing level (mean of 500, 1000, 2000 and 4000 Hz).
OR
Single-sided sensorineural deafness (SSD):
European sites: Bone conduction thresholds with a pure tone average PTA4 of < 30dB hearing level (mean of 500, 1000, 2000 and 4000 Hz) in the good ear.
US sites: Air conduction thresholds with a pure tone average PTA4 of 20 dB hearing level (mean of 500, 1000, 2000 and 3000 Hz) in the good ear OR Subject is indicated for an AC CROS but-for some reason-cannot or will not use an AC CROS.
No previous bone conduction implant on the side of the skull to be implanted. Signed informed consent.
Exclusion Criteria
Subjects that are scheduled for simultaneous bilateral implant surgery. The investigation is limited to subjects with unilateral use of the Baha Attract System (however, bilateral hearing loss is not an exclusion criterion).
Suitable implant position for the BI300 Implant (4 mm or 3 mm) not found during surgery due to insufficient bone quality and/or bone thickness.
Less than 3 mm soft tissue thickness at the planned implant site. Subjects that have received radiation therapy at the same side of the skull where the Baha Attract System will be positioned.
Condition that could jeopardise osseointegration and/or wound healing as judged by the investigator (e.g. osteoporosis, psoriasis, use of corticosteroids).
Uncontrolled diabetes as judged by the investigator. Condition that may have an impact on the outcome of the investigation as judged by the investigator.
Unable to follow investigational procedures (e.g. to complete quality of life scales).
Participation in another investigation with pharmaceuticals and/or medical device.
Data sourced from ClinicalTrials.gov (NCT02022085). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.